Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors

Rachel Sanborn, See full list of authors in comments

Research output: Other contribution

Original language	Undefined/Unknown
State	Published - Nov 1 2023

Name	Articles, Abstracts, and Reports

Access to Document

@misc{4121ed1225204ad09a202b112da7500c,

title = "Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors",

author = "Rachel Sanborn and comments, {See full list of authors in}",

year = "2023",

month = nov,

day = "1",

language = "Undefined/Unknown",

series = "Articles, Abstracts, and Reports",

type = "Other",

}